Repligen | RGEN - Operating Profit


Repligen reported $12.68M in Operating Profit for its fiscal quarter ending in September of 2025.





Operating Profit Change Date
Agilent USD 443M 66M Sep/2025
Align Technology USD 224.71M 40.06M Dec/2025
Bio Techne USD 54.46M 6.8M Dec/2025
BioMarin Pharmaceutical USD 198.39M 230.08M Dec/2025
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Bruker USD 76.3M 7.6M Dec/2025
Charles River Laboratories USD 75.82M 57.98M Dec/2025
Danaher USD 1.5B 348M Dec/2025
Dentsply International USD 512M 401M Sep/2025
Exact Sciences USD -25M 22.85M Sep/2025
General Electric Aerospace USD 1.77B 536M Dec/2025
Henry Schein USD 186M 12M Dec/2025
Illumina USD 256M 6M Dec/2025
IQVIA Holdings USD 2.68B 2.1B Dec/2025
Mettler Toledo International USD 351.93M 57.73M Dec/2025
Myriad Genetics USD -23.3M 10.8M Sep/2025
OraSure Technologies USD -6M 3.26M Sep/2024
Pacific Biosciences Of California USD -64.08M 111.77M Sep/2024
Pfizer USD 4.65B 3.99B Dec/2025
Repligen USD 12.68M 6.72M Sep/2025
Revvity USD 145.83M 47.49M Dec/2025
Standard Biotools USD -23.47M 230K Sep/2025
Thermo Fisher Scientific USD 2.3B 226M Dec/2025
Waters USD 270.52M 78.4M Dec/2025
West Pharmaceutical Services USD 162.5M 5.1M Dec/2025